Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates

Digestive Diseases

Volumn 29, Issue 1, 2011, Pages 85-88

  Poupon, Raoul ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Peroxisome proliferator activated receptor; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

BEZAFIBRATE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CLOFIBRATE; CORTICOSTEROID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIFAMPICIN; URSODEOXYCHOLIC ACID; VITAMIN D;

BILE DUCT STONE; CLINICAL FEATURE; COMMON BILE DUCT STONE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; OSTEOPENIA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; BUDESONIDE; FEMALE; FIBRIC ACIDS; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 79959519136     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000324139     Document Type: Conference Paper

References (20)

1. Pares A, Caballeria L, Rodes J: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-720. (Pubitemid 43374522)
2. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group: Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101:2044-2050. (Pubitemid 44337630)
3. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R: The effect of ursode-oxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128:297-303. (Pubitemid 40431083)
4. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE: Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999; 29:39-43. (Pubitemid 29023983)
5. Corpechot C, Carrat F, Poupon R, Poupon RE: Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122:652-658. (Pubitemid 34173817)
6. Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, et al: Triple therapy with ursodeoxycholic acid, prednisone and azathio-prine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 1998; 29:736-742. (Pubitemid 28505930)
7. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF: A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992; 15:336-344.
8. Wolfhagen FH, van Buuren HR, Schalm SW: Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth J Med 1994; 44: 84-90. (Pubitemid 24089456)
9. Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U: Ursodeoxycholic acid and prednisolone versus ursodeoxy-cholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996; 25:49-57. (Pubitemid 26267092)
10. Greenberg GR, Feagan BG, Martin F, et al: Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-841. (Pubitemid 24289710)
11. Wiegand J, Schuler A, Kanzler S, et al: Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25:927-934. (Pubitemid 41404011)
12. Leuschner M, Maier KP, Schlichting J, et al: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117:918-925. (Pubitemid 29468235)
13. Rautiainen H, Karkkainen P, Karvonen AL, et al: Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41:747-752. (Pubitemid 40462936)
14. Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD: Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31: 318-323. (Pubitemid 30078594)
15. Rabahi N, Chrétien Y, Gaouar F, Wendum D, Serfaty L, Chazouillères O, Corpechot C, Poupon R: Triple therapy with ursodeoxy-cholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010; 34: 283-287.
16. Schaffner F: Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969; 57: 253-255.
17. Summerfield JA, Elias E, Sherlock S: Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. Gastroenterology 1975; 69: 998-1000.
18. Lovett-Racke AE, Hussain RZ, Northrop S, et al: Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004; 172: 5790-5798. (Pubitemid 38542085)
19. Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28:551-558. (Pubitemid 350101420)
20. Iwasaki S, Ohira H, Nishiguchi S, et al: The efficacy of ursodeoxycholic acid and bezafi-brate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008; 38:557-564. (Pubitemid 351622281)